Additional file 3 of IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas

Supplementary Material 3. Supp. Fig 2. (A) A17 patient-derived human melanoma. was implanted into NSG (n=9) and NSG with HuHSC (n=15) mice. On day 35 (IRF2KO) and day 77 (EV) tumors were harvested and MHC I expression was analyzed by flow cytometry. (B-E) B16F0 EV or IRF2 KO cells were implanted into humanized C57Bl/6 mice and treated as indicated. Cell surface MHC I (C) and PDL1 (D) expression levels and tumor weight (E) of B16F0 EV vs IRF2KO tumors were quantified on day 15-17 in vivo. (F) shows corresponding tumor growth data.